HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy.

Abstract
In human filariasis, the predominant serum antibody is IgG4, accompanied by significant IgE production. The ratio of IgG4 to IgE is highest in asymptomatic microfilaremic carriers, while chronic disease is associated with elevated IgG1-3. The changes in isotypes following chemotherapy with diethylcarbamazine (DEC) were studied in 2 groups of Brugia malayi-infected patients from Sumatra and South Kalimantan, Indonesia. Similar results were obtained from each group. IgG4 levels decreased sharply (65%-78%) within 12 months. IgG1 levels declined in a less consistent and extreme manner, and levels of IgG2 and IgG3 declined only in patients with elephantiasis, who also had the highest initial levels of these antibodies. IgE responses were relatively stable to therapy in microfilaremic patients (7%-28% reduction) and showed only moderate decline (56% over 2 years) in elephantiasis patients. Active filarial infection is thus associated with specific IgG4 antibodies, but there is independent expression of the IgE and IgG4 isotypes in filariasis.
AuthorsA K Atmadja, R Atkinson, E Sartono, F Partono, M Yazdanbakhsh, R M Maizels
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 172 Issue 6 Pg. 1567-72 (Dec 1995) ISSN: 0022-1899 [Print] United States
PMID7594718 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Helminth
  • Filaricides
  • Immunoglobulin G
  • Immunoglobulin E
  • Diethylcarbamazine
Topics
  • Adult
  • Animals
  • Antibodies, Helminth (blood)
  • Brugia malayi (immunology)
  • Cross-Sectional Studies
  • Diethylcarbamazine (therapeutic use)
  • Filariasis (drug therapy, immunology)
  • Filaricides (therapeutic use)
  • Humans
  • Immunoglobulin E (blood)
  • Immunoglobulin G (blood, classification)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: